UK reports 216 suspected GLP-1 drug deaths, experts urge caution

UK regulators have received 216 death reports linked to suspected adverse reactions from GLP-1 drugs. The figures have renewed focus on safety monitoring as use widens for diabetes and weight loss.More than 200 deaths in the UK have now been reported as suspected adverse reactions involving GLP-1-based drugs, raising fresh concerns around a class of medicines that has rapidly moved from specialist diabetes care into the mainstream weight-loss conversation.The figures, reported through the UK Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card system, are striking.There have been 120 reported deaths involving tirzepatide, sold as Mounjaro; 59 involving semaglutide, the active ingredient in drugs including Wegovy, Ozempic and Rybelsus; and 37 involving liraglutide, sold as Saxenda.That adds up to 216 reported deaths. The MHRA has also received more than 158,000 reports of adverse reactions associated with these medicines. But there is an important distinction that can easily get lost in a headline: these are reports of suspected adverse reactions, not deaths proven to have been caused by GLP-1 drugs.GLP-1-based therapies are powerful medicines that mimic gut hormones involved in insulin secretion, digestion and appetite regulation. First developed to treat type 2 diabetes, they have emerged as blockbuster obesity medicines worldwide after their dramatic weight-loss results were established. That distinction is crucial when judging the safety of medicines used by millions of people.WHAT’S BEHIND THE ALARMThe Yellow Card system is an early-warning mechanism. Doctors, patients and others can report a suspected adverse reaction when they believe a medicine may have played a role. Such reports can help regulators identify patterns that warrant further investigation.They do not, by themselves, establish causality.The MHRA has stressed that a reported adverse reaction or death does not necessarily mean the medicine caused it. The UK has also issued millions of GLP-1 prescriptions, meaning reporting volumes can rise as use expands and awareness of possible side effects grows.The regulator says the benefits of GLP-1 receptor agonists currently outweigh their potential risks when the medicines are used according to their authorised indications.Dr Anoop Misra, veteran diabetologist and researcher, said the figures need to be interpreted cautiously. “Yellow Card numbers reflect raw associations, not proven causation,” he said.GLP-1 based medications are predominantly prescribed to people with type 2 diabetes or severe obesity, populations that already face significantly elevated baseline risks for heart attacks, strokes and kidney disease. At the same time, large clinical trials involving tens of thousands of patients have shown that GLP-1s can reduce overall cardiovascular deaths by 12% to 20%.Pharmacovigilance reports remain important because even large clinical trials cannot capture every rare event that may emerge when medicines are used extensively in the real world.The appropriate response, therefore, is neither panic nor complacency, but investigation.THE INDIAN CONTEXTThe issue is particularly relevant in India, where GLP-1-based medicines have become one of the fastest-growing areas of the diabetes and obesity market.The Indian GLP-1 market has expanded dramatically over the past year. Recent market data put the domestic market for drugs such as semaglutide and tirzepatide around Rs 2,215 crore in July 2026, nearly five times its level a year earlier.The arrival of lower-cost generic semaglutide has further expanded access.That growth is unfolding alongside enormous public enthusiasm for rapid weight loss. Social media, celebrity influence and aggressive marketing have helped turn medicines originally developed primarily for metabolic diseases into cultural shorthand for getting thinner.Concerns about inappropriate use and access among people who may not medically need these drugs have already been raised in India. Mumbai-based diabetologist and metabolic disease specialist Dr Rajiv Kovil said the UK figures should be viewed as safety signals rather than proof of cause and effect.“These numbers deserve investigation, not interpretation,” he said.He also stressed that the focus should be on responsible prescribing, appropriate patient selection, careful dose escalation and regular follow-up. GLP-1 drugs are powerful medicines, not over-the-counter weight-loss accessories.THE KEY LESSONSThere are legitimate reasons for the excitement. These drugs can produce substantial weight loss and improve blood sugar control, while major trials have also demonstrated important cardiovascular benefits in appropriate patient populations.But benefits seen in controlled clinical settings do not mean everyone seeking rapid weight loss is automatically a suitable candidate.According to senior gastroenterologist and medical researcher Dr Rajeev Jayadevan, the UK deaths must be considered against the much larger population using these medicines.People with obesity and diabetes may have underlying conditions that can lead to stroke, heart attack or kidney failure, he noted, meaning a death occurring during treatment does not necessarily establish that the medication caused it.He pointed to the SELECT trial, which showed a 20% reduction in cardiovascular deaths among people using these medications, as evidence of the broader picture that Yellow Card reports alone cannot provide.There are nevertheless areas that warrant continued scrutiny. Dr Jayadevan pointed to rare complications such as acute pancreatitis, for which questions about the precise level of risk remain under study.He also highlighted concerns in the UK around fake or locally compounded medicines, where impurities or incorrect dosing can introduce additional risks.As access expands, the concern is therefore not only the medicine itself, but what happens around it: self-medication, inappropriate prescribing, rapid dose escalation, counterfeit products, inadequate screening and insufficient follow-up.- EndsPublished On: Aug 11, 2026 14:12 IST